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The mammalian target of rapamycin (mTOR) protein com-plex belongs to the phosphatidylinositol 3-kinase (PI3K)-
related family of kinases. Activation occurs through a com-
plex signaling network in which activation of a
transmembrane receptor leads to activation of PI3K, subse-
quently stimulating Akt phosphorylation and signaling
through mTOR to initiate protein synthesis (Figure 1). Sig-
naling through mTOR can have multiple functions, in that
mTOR complex 1 (mTORC1) is responsive to rapalogs,
whereas mTOR complex 2 (mTORC2) is relatively insensi-
tive to rapalogs, and both are involved in negative feedback
loops which modulate signaling. The mTOR pathway is
constitutively activated in non-small cell lung cancer
(NSCLC) as evidenced by phosphorylation of mTOR (69%),
p70 s6K (81%), and p4EBP-1 (79%) in tumor tissue. In
addition, activation of Akt occurs frequently in NSCLC and
has been associated with tobacco carcinogen-induced cellular
transformation, promotion of tumor invasion, angiogenesis,
and resistance to therapy.1,2 More than 70% of NSCLC
tumors demonstrate activation of Akt at both the ser473 and
thr308 phosphorylation sites, which is associated with a
shorter survival.3 Furthermore, phosphorylation of Akt can be
inhibited by the phosphatase and tensin homolog gene
(PTEN), and loss of PTEN is also associated with poor
prognosis in NSCLC.4 Therapy with rapalogs as single agents
results in limited tumor responses in lung cancer, and pro-
longed treatment induces resistance, which seems to be me-
diated by Akt signaling.5 Blocking PI3K may decrease the
up-regulation of Akt signaling induced by mTOR inhibition.
Thus, combined blockade of PI3K/Akt and mTOR may result
in enhanced antitumor activity.
mTOR Inhibition
Sirolimus (rapamycin) is an oral rapalog that has dem-
onstrated synergism in combination with pemetrexed in vitro
and in vivo in NSCLC models. Pemetrexed is an antifolate
drug that blocks multiple pathways in folate metabolism.
Recently, a downstream target has been described, aminoimi-
dazolecarboxamide ribonucleotide formyltransferase, which
results in inhibition of mTOR through increased cellular
ZMP.6 Accumulation of ZMP activates AMP-activated pro-
tein kinase, which in turn, blocks mTOR and subsequent
protein synthesis and cell growth. Therefore, the combination
of pemetrexed and mTOR inhibition may further decrease
signaling through the mTOR pathway in NSCLC. A phase
I/II trial evaluating pemetrexed and sirolimus in patients with
advanced NSCLC with tumors that demonstrate activation of
mTOR is ongoing. A phase I dose escalation will be followed
by a phase II portion that requires a biopsy sample to
establish mTOR activation before drug administration and
after cycle 2 of therapy. The end points include determination
of dose-limiting toxicities and maximum tolerated dose in the
phase I portion; and response rate, PFS, and modulation of
mTOR activity in the phase II portion. Twelve patients are
evaluable to date, with three partial responses.
Everolimus has been studied extensively in NSCLC as
monotherapy and in combination with chemotherapy and
epidermal growth factor receptor (EGFR) tyrosine kinase
inhibition (TKI). A phase I study assessed the combination of
gefitinib and everolimus in former smokers, which resulted in
two partial responses in eight evaluable patients.7 This led to
a phase II trial that enrolled patients who were current or
former smokers into two cohorts, untreated versus prior
chemotherapy, and the primary end point was objective
response rate. Sixty-two patients were enrolled, and eight
(13%) patients had partial or complete response, five un-
treated, and three previously treated. Two responders in the
untreated cohort harbored KRAS mutations (both G12F), two
carried EGFR mutations, and one had neither. In the previ-
ously treated cohort, one patient harbored an EGFR mutation,
and two were wild type for both EGFR and KRAS. The
most common drug-related toxicities included rash, diar-
rhea, oral ulcerations, and fatigue. Two patients were
removed from study for pulmonary toxicity. The role of
mTOR inhibition in G12F KRAS mutated NSCLC is under
investigation. Additional studies of everolimus have at-
tempted to define molecular end points through preopera-
tive evaluation in NSCLC tumors. A study evaluating
everolimus given for 3 weeks preoperatively has enrolled
12 patients to date and has found a reduction in pS6 with
up-regulation of pAkt after therapy.
Temsirolimus is an ester of sirolimus and has shown
minimal activity as monotherapy in lung cancer. Combina-
tion therapy with EGFR TKI, chemotherapy, vascular endo-
thelial growth factor (VEGF) inhibitors, and VEGF receptor
inhibitors have demonstrated the potential for augmented
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tumor responses in a variety of tumor types, although com-
bination trials in NSCLC remain in early phases.
TORC1 and TORC2 Inhibition
OSI-027 attenuates Akt activation through inhibition of
both mTORC1 and mTORC2. The compound has been
shown to induce apoptosis in multiple solid tumor and he-
matologic malignancy models, including those resistant to
rapamycin. It has been shown to potentiate chemotherapy-
induced apoptosis and to decrease VEGF production and
blood vessel formation. A phase I trial is ongoing evaluating
weekly, intermittent, and continuous dosing of OSI-027, and
the recommended phase 2 dose has been determined for all
cohorts. Pharmacokinetics indicate a dose response for in-
creasing concentrations, and pharmacodynamic data evaluat-
ing p4EBP-1 levels in peripheral blood mononuclear cells
demonstrate inhibition of mTOR signaling.
AZD8055 inhibits both mTORC1 and mTORC2, re-
sulting in increased tumor apoptosis and decreased cell pro-
liferation. It has been shown to induce dose-dependent anti-
tumor activity and to modulate pS6 and pAkt. A phase I trial
is ongoing and has enrolled 38 patients, showing a dose-
dependent pharmacodynamic modulation of pAkt and
p4EBP-1 in peripheral blood mononuclear cells. The most
common toxicities include rash, neutropenia, mucositis, hy-
perinsulinemia and mild hyperglycemia.
PI3K Inhibition
PI3K pathway inhibition may inhibit tumor growth and
proliferation and sensitize cancer cells to programmed cell
death. BEZ235 is an imidazo[4,5-c]quinoline derivative and
acts as a dual PI3K and mTORC1 and mTORC2 inhibitor.
The compound binds the ATP-binding cleft of the p110
subunit of PI3K and mTORC1 and mTORC2. It induces G1
cell cycle arrest and apoptosis and inhibits downstream ef-
fector activation in multiple malignancies. It has demon-
strated antitumor activity in xenograft models harboring PI3K
alterations. It has been shown to inhibit VEGF-induced an-
giogenesis and microvessel permeability with blockade of
endothelial nitric oxide synthase. A phase I trial has been
completed with 59 subjects and two partial responses. The
drug demonstrated dose-dependent PI3K inhibition as mea-
sured by elevation of plasma C-peptide levels.
PX-866 is a PI3K inhibitor, which induces antitumor
effects through the inhibition pAkt. Evaluation of markers to
determine response demonstrates resistance in tumors with
mutant KRAS, whereas loss of PTEN and alterations in PI3K
predicts for sensitivity.
Akt Inhibition
Combinations of Akt and EGFR inhibition may prove
beneficial in EGFR TKI-resistant NSCLC. PHT427 is an Akt
inhibitor, which binds to the phosphorylation domains of Akt
and phosphoinositol-dependent kinase 1 (PDK1), inhibits
phosphorylation at ser473, and decreases tumor growth. Its
effects have been most pronounced in KRAS-mutant NSCLC
when used in combination with erlotinib.
Hepatocyte growth factor can induce EGFR TKI resis-
tance through c-met, and coexpression of c-met and EGFR
can stimulate synergistic tumor cell growth. Erlotinib and
MK2206 have been shown to augment antitumor effects in
both KRAS/EGFR wild-type and EGFR-mutant NSCLC mod-
els. Furthermore, MK2206 can reverse hepatocyte growth
factor-induced resistance to erlotinib. A phase II trial is
planned to evaluate patients with advanced NSCLC who have
progressed on erlotinib after prior response to EGFR TKI
therapy. Patients will be stratified by EGFR mutation status
FIGURE 1. Phosphatidylinositol
3-kinase (PI3K)/Akt/mammalian
target of rapamycin (mTOR) signal-
ing cascade. Signaling through a
transmembrane receptor activates
the PI3K signaling network to
phosphorylate Akt and promote
cell proliferation and invasion
through mTOR. Multiple feedback
loops exist within this signaling
cascade, and a number of inhibi-
tors are in development to target
this pathway in cancer.
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and will receive erlotinib daily and MK2206 on an every
other day schedule. Tumor tissue will be evaluated for Akt
pathway inhibition.
FUTURE DIRECTIONS
Selection of patients who are responsive to the mTOR/
PI3K/Akt pathway is essential as these agents are developed
for NSCLC therapy. Studies are underway to identify key
molecular and genetic changes, which may be important in
regulating this pathway. Two tumor suppressor genes have
been linked to promoting NSCLC and mTOR signaling.
LKB1 has serine threonine kinase activity and controls cell
differentiation, cell polarity, and energy control,8 and alter-
ations occur in approximately 39% of NSCLC. BRG1 is
important in ATP-dependent chromatin remodeling, cell cy-
cle arrest, DNA repair, cell differentiation and regulation of
apoptosis,9 and 33% of NSCLC harbor mutations. LKB1 and
BRG1 inactivating mutations correlate with a unique gene
expression profile in NSCLC that affects many crucial sig-
naling pathways. Importantly, BRG1 plays an essential role in
peripheral airway development, whereas LKB1 inhibits pro-
liferation and invasion through the mTOR pathway. Further
delineation of these genes and others involved in signaling
through mTOR will enhance our understanding of lung can-
cer pathogenesis. Opportunities for targeting this axis require
an improved understanding of the biology and signaling
within the individual tumors, and combination treatments
with rapalogs and PI3K inhibitors or novel agents may
provide new approaches.
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